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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

DIET STARTS MONDAY:
AN ANALYSIS OF CURRENT U.S. DIETARY SUPPLEMENT REGULATIONS
THROUGH AN INTERNATIONAL COMPARISON
I. INTRODUCTION
It only takes a few moments walking through a grocery store, browsing
through a magazine, or even just flipping through the channels to
understand the massive role that dietary supplements play in American
culture. In 2008, American consumers spent roughly $25 billion on dietary
supplements,1 making up a sizeable portion of the massive $228.3 billion
global nutrition industry.2 Dietary supplement use has soared in popularity
to an estimated 150 million Americans3—approximately half of the U.S.
population.4 In line with their popularity in the United States, dietary
supplements are highly popular abroad as well. Up to seventy percent of all
Canadians take some form of supplement5 and European consumers are
responsible for roughly seventeen percent of the entire global dietary

1. Carlotta Mast, Supplement Industry Adds $61 Billion to U.S. Economy, NUTRITION
BUS. J., May 28, 2009, http://blog.nutritionbusinessjournal.com/nbj/2009/05/28/supple
ment-industry-adds-61-billion-to-us-economy/. See also Patrick Rea, 2009 Supplement
Industry – What Can We Expect?, NUTRITION BUS. J., Nov. 11, 2008, http://blog.nutrition
businessjournal.com/nbj/2008/11/11/2009-supplement-industry-what-can-we-expect/
(noting that in 2008, in spite of the economic downturn, total sales figures would likely be
higher than 2007 due to sales-growth in multivitamins and a renewal of consumer interest in
herbs and vitamin D).
2. NUTRITION BUS. J., GLOBAL SUPPLEMENT & NUTRITION INDUSTRY REPORT 2007 (2007),
http://nutritionbusinessjournal.com/nutrition-industry/market-research/global_supplement_
nutrition_industry_report_2007/index.html (demonstrating the global nutrition industry
includes dietary supplements, but also includes other products like natural and organic foods).
3. Press Release, Council for Responsible Nutrition, Issues Surrounding Healthcare Key
Priority for Supplement Users (Jan. 15, 2009), available at http://www.crnusa.org/prpdfs/
CRNPR09_ConsumerHC011509.pdf.
4. See Press Release, U.S. Census Bureau, Census Bureau Projects U.S. Population of
305.5 Million on New Year’s Day (Dec. 29, 2008), available at http://www.census.gov/Press
Release/www/releases/archives/population/013127.html.
5. CANADIAN HEALTH FOOD ASS’N, Western Canadians Big Users of Natural Health
Products in a $2.5 Billion Dollar Industry (Apr. 7, 2007) (on file with author) (statement of
Canadian Health Food Association president Valerie Bell) (“Canada’s natural health products
sector has become a significant contributor to the Canadian economy.”).
123
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supplement market.6 Due to the popularity of dietary supplements and the
increasing size of the global industry, the importance of product safety has
grown into a main concern for governmental regulatory bodies.7
Depending on the country, dietary supplements may have different
definitions and different levels of regulation, if any. In the United States,
dietary supplements are classified by the Dietary Supplement Health and
Education Act of 1994 (DSHEA).8 Under DSHEA, a dietary supplement can
generally be described as a product taken orally that contains a “dietary
ingredient” intended to supplement the diet. These dietary ingredients may
include vitamins, minerals, herbs, and amino acids, among others.9
Dietary supplement regulations in the United States are distinct from
both food and pharmaceutical regulations. Regulated primarily under
DSHEA, the dietary supplement industry receives specific guidance for
manufacturing and labeling of dietary supplements10 Importantly, in a stark
departure from the regulation of pharmaceuticals, dietary supplement
manufacturers do not have to prove the safety of their products before they
enter the market; rather the burden of proof is on the U. S. Food and Drug
Administration (FDA).11 Unfortunately, there is a subsequent history of
unsafe dietary supplement products that have made their way into the
market and have caused harm and even death to consumers.12 Public

6. See Peter Zambetti, Global Market Growth for Dietary Supplements (Apr. 17, 2008)
(noting that Western and Eastern Europe’s global market shares for dietary supplements are
14.4% and 2.7%, respectively), http://www.naturalproductsinsider.com/articles/2008/04/
global-market-growth-for-dietary-supplements.aspx.
7. For example, depending on the country and regulatory framework, dietary
supplements may either be regulated with specific guidance (United States) or they may be
regulated under general food or drug regulations (Australia). See infra part III.
8. Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108
Stat. 4325 (codified as amended in scattered sections of 21 U.S.C.).
9. See 21 U.S.C. § 321(ff) (2006).
10. Id. §§ 342(g), 343(s).
11. Id. § 342(f).
12. See e.g., U.S. FOOD & DRUG ADMIN., INFORMATION PAPER ON L-TRYPTOPHAN AND 5HYDROXY-L-TRYPTOPHAN (2001) [hereinafter FDA INFORMATION PAPER] (noting that in 1989 an
epidemic outbreak of eosinophilia-myalgia syndrome (EMS), which resulted in thirty-seven
known deaths, occurred in the U.S. due to the use of dietary supplements containing Ltryptophan), available at http://www.cfsan.fda.gov/~dms/ds-tryp1.html. See also Editorial,
The Ephedra Ban Is Not Enough, N.Y. TIMES, Jan. 5, 2004, at A16 (discussing the dangers of
ephedra-containing weight loss products, “Ephedra has generated far more reports of adverse
effects than any other supplement and has been linked to cases of heart attack, stroke and
sudden death”).
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outcry cast a shadow over the industry as a seeming lack of regulation was
blamed for such adverse events.13
U.S. lawmakers responded in the last few years to complaints
concerning the need for more stringent dietary supplement rules with the
adoption of two important regulatory changes. In 2006, the Dietary
Supplement and Non-prescription Drug Consumer Protection Act
(DSNDCPA) was passed, requiring dietary supplement manufacturers to
report to the FDA any serious adverse events potentially associated with their
products.14 The DSNDCPA became effective on December 22, 2007.15
Also, in June 2007, Congress adopted the FDA’s proposal for Current
Good Manufacturing Practices for dietary supplements (CGMPs).16 The
CGMPs create the minimum current good manufacturing practices for
dietary supplement manufacturing, packaging, labeling, or holding of
dietary supplements, in an effort to increase product quality17 and to help
create a level playing field for supplement manufacturers.18
With the passage of DSHEA, the DSNDCPA, and the CGMPs, it may
appear that the government is strengthening its grip on the dietary
supplement industry.
But in reality, the FDA’s power over dietary
supplement manufacturers remains relatively weak. The passage of DSHEA
did not create a framework to restrict dietary supplements; it arguably
created the opposite. By placing the burden of proof on the government,
DSHEA explicitly guarantees that dietary supplement manufacturers do not
have to prove their products’ safety before marketing and sale of the
products to consumers. Even with the passage and implementation of the
DSNDCPA and the CGMPs, dietary supplement regulation in the United
States is widely open to criticism that the regulations do not ensure safety.19

13. See e.g., David Lazarus, Supplement Makers Need Stricter FDA Oversight, L.A. TIMES,
Sept. 3, 2008, at C1 (arguing that dietary supplements should undergo pre-market testing in
order to protect consumers).
14. Dietary Supplement and Non-prescription Drug Consumer Protection Act, Pub. L. No.
109-462, 120 Stat. 3469, 3469 (2006) (codified at 21 U.S.C. § 379aa-1(b) (2006)).
15. Id. § 379aa-1(i).
16. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 72 Fed. Reg. 34942, 34942 (June 25, 2007)
(to be codified at 21 C.F.R. pt. 111).
17. Id.
18. Todd Zwillich, FDA OKs Dietary Supplement Regulations, WEBMD HEALTH NEWS, June
22, 2007 (quoting Steve Mister, President and CEO of industry lobbying group, The Council
for Responsible Nutrition, “I’m sure we won’t agree with everything in the rule, but we are
pleased that the new GMPs are here as it’s a step forward for our industry.”), www.webmd.
com/news/20070622/fda-oks-dietary-supplement-regulations.
19. See e.g., Katherine Wong, New Mandatory Reporting Requirements for Dietary
Supplements and Nonprescription Drugs Solve Very Little, 35 J.L. MED. & ETHICS 336, 336
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Further, when compared to dietary supplement regulations in jurisdictions
that are also heavily influenced by dietary supplements—like the European
Union, Japan, Canada, and Australia—current regulations in the United
States are much less restrictive. However, as this note argues, “less
restrictive” does not necessarily mean that the regulations in the U.S. are
inferior when compared to those abroad. With the exponential growth in
this newly regulated industry, it appears that most countries have yet to
figure out how to adequately regulate dietary supplements. Therefore, a
critique of the recent dietary supplement regulations in the United States and
a comparison to dietary supplement regulations abroad is necessary to
provide guidance on how dietary supplement regulation in the United States
should develop, and also to provide caution for potential problems.
Part II of this article provides a historical background of dietary
supplements’ turbulent past and their seemingly ever-increasing popularity.
Next, as dietary supplement regulations around the world continue to
change, Part III provides an overview of current dietary supplement
regulations in the United States, European Union, Japan, Canada, and
Australia, and addresses criticisms of DSHEA, the DSNDCPA, and the
CGMPs. Finally, Part IV analyzes the differences between the varying
regulatory frameworks abroad with the dietary supplement regulations
currently in place in the United States. Based upon an international
comparison of dietary supplement regulations, this note concludes that the
United States is not alone in its struggle to properly address the regulatory
needs of the expanding dietary supplement industry, and therefore, DSHEA,
the DSNDCPA, and the CGMPs may be the targets of excessive criticism.
II. HISTORY OF DIETARY SUPPLEMENTS
Although the term “dietary supplement” may be relatively new, the
beneficial properties of certain vitamins and herbs have been appreciated
for centuries. Treatments using ancient Chinese herbs date back 2,500
years to when healers employed herbal remedies to treat various
afflictions.20 Such remedies are still used today around the world in what is
now known as “traditional Chinese herbal medicine.”21 Likewise, Native
Americans have used herbs such as echinacea for more than 400 years to

(2007) (arguing that the DSNDCPA addresses some problems with DSHEA, but “it seems
unlikely that it will substantially increase manufacturer or supplier accountability”).
20. See College of Traditional Chinese Medicine, University of Technology Sydney,
History of Chinese Herbal Medicine, (noting that Chinese herbal medicine grew out of beliefs
that herbs could protect individuals from evil forces), http://www.science.uts.edu.au/centres/
tcm/herbal.html (last visited Nov. 22, 2009).
21. See id.
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treat wounds and injuries.22 In 2006 alone, American consumers spent an
estimated $129 million on echinacea.23
The understanding of vitamin properties was not developed until more
recently, and scurvy played an important role. Caused by a deficiency in
vitamin C consumption, scurvy can manifest itself through skin bumps, leg
hemorrhages, and swollen gums.24 “If we exclude straightforward famine,
scurvy is probably the nutritional deficiency disease that has caused most
suffering in recorded history.”25 In 1747, a British naval physician
conducted an experiment where he provided lemons and limes to sailors
who suffered from scurvy and quickly concluded that there were properties
in the fruits that helped the sailors battle scurvy’s serious effects.26
Consequently, British sailors carried limes onboard as part of their diets and
earned the nickname “limeys.”27 Although the sailors did not know it at the
time, the vitamin C that treated and protected them from scurvy would
someday become one of the most popular dietary supplements in the world.
Over time, the effects of vitamins, herbs, and amino acids continued to
draw attention from scientists and ultimately progressed into the synthesis of
thousands of specific dietary supplements that are available to consumers
around the world.
Today, dietary supplements maintain a high level of popularity because
most consumers believe they are safe, effective, and good for health.28
However, the dietary supplement industry is no stranger to controversy. In
1989, a dietary supplement containing the amino acid L-tryptophan was
responsible for an outbreak of eosinophilia-myalgia syndrome (EMS) in the
United States.29 EMS is a “painful blood disorder [that] can cause high
fever, rash, weakness and shortness of breath, among other symptoms.”30
The manufacturer of the dietary supplement, Showa Denko Inc., a Japanese
company, cut corners in their purification procedures and experimented with

22. University of Maryland Medical Center, Medical Reference, Echinacea, (“Throughout
history people have used echinacea to treat scarlet fever, syphilis, malaria, blood poisoning,
and diphtheria.”) http://www.umm.edu/altmed/articles/echinacea-000239.htm (last visited
Nov. 20, 2009).
23. Elizabeth Weise, Lancet: Echinacea Does Fight Colds, USA TODAY.COM, June 25,
2007, http://www.usatoday.com/news/health/2007-06-25-echinacea-colds_N.htm.
24. Roger K. French, Scurvy, in THE CAMBRIDGE WORLD HISTORY OF HUMAN DISEASE 1000,
1001 (Kenneth F. Kiple et al. eds., 1993).
25. KENNETH J. CARPENTER, THE HISTORY OF SCURVY & VITAMIN C vii (1988).
26. S.O. Waife, Lind, Lemons, and Limeys, 1 J. CLINICAL NUTRITION 471, 472 (1953).
27. Id. at 472-73.
28. MERCK RESEARCH LABORATORIES, THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 2724
(Mark H. Beers et al. eds., 18th ed., 2006) [hereinafter MERCK MANUAL].
29. FDA INFORMATION PAPER, supra note 12.
30. Illness Is Tied to Way Diet Additive Was Made, N.Y. TIMES, Aug. 9, 1990, at D24.
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bacteria to accelerate and increase the efficiency of production of their
dietary supplement product that was used as a sleep aid.31 As a result,
there were more than 1,500 reported cases of EMS associated with Ltryptophan—of which there are at least thirty-seven known deaths.32
Further, the actual number of people affected is estimated to be much
higher.33 The FDA consequently took action to limit the availability of
dietary supplements that contain L-tryptophan through advising consumers
about the substance’s potential effects.34
Similar to L-tryptophan, the dietary supplement ephedra has a deadly
past. Ephedra was marketed as a weight loss and bodybuilding supplement
in the late 1990s and early 21st century.35 The supplement is an
“amphetamine-like herb”36 that has been linked to seizure, heart attack,
stroke, and death.37 By the end of 2001, ephedra was banned by the
National Football League, National Collegiate Athletic Association, and the
International Olympic Committee.38 Finally, at the beginning of 2004,
ephedra became the first FDA-banned dietary supplement.39 Unfortunately,
the ban was too late for many as it is believed that dietary supplements
containing ephedra contributed to 155 deaths.40 The FDA ban stated that
products containing ephedra “present an unreasonable risk of illness or
injury,” and therefore are unsafe for consumers’ use.41
The failure to resolve the ephedra issues until several years after the
beginning of linked deaths is believed to be one of the biggest problems to
face the dietary supplement industry in the first decade since the enactment

31. National Eosinophilia-Myalgia Syndrome Network, Eosinophilia-Myalgia Syndrome,
http://www.nemsn.org (last visited Nov. 21, 2009).
32. FDA INFORMATION PAPER, supra note 12.
33. Id. (“Some individuals suffering from L-tryptophan-related EMS have recovered, while
other individuals’ illnesses have persisted or worsened over time.”).
34. See id.
35. See Nationwide Ban on Ephedra Goes into Effect: Judge Rejects Manufacturers’
Request to Halt Action, Apr. 13, 2004 [hereinafter Ephedra Ban], http://www.msnbc.msn.
com/id/4721505/.
36. Id.
37. JENNA HOLLENSTEIN, UNDERSTANDING DIETARY SUPPLEMENTS 53 (2007).
38. Ephedra Ban, supra note 35.
39. Id.
40. Id.
41. News Release, U.S. Dep’t of Health & Human Services, FDA Announces Plans to
Prohibit Sales of Dietary Supplements Containing Ephedra: Consumers Advised to Stop Using
Ephedra Products Immediately (Dec. 30, 2003) (quoting FDA Commissioner Mark B.
McClellan, “Consumers should stop buying and using ephedra products right away, and FDA
will make sure consumers are protected by removing these products from the market as soon
as the rule becomes effective.”), available at http://www.hhs.gov/news/press/2003pres/200
31230.html.
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of DSHEA.42
Annette Dickinson, the President of the Council for
Responsible Nutrition, testified in front of the Subcommittee on Human
Rights and Wellness that the delay in assessing the issues with ephedra was
so monumental that it undermined consumer confidence in the entire dietary
supplement industry.43
However, for each L-tryptophan or ephedra controversy, there are
thousands of dietary supplements that have not been linked to deaths or
serious adverse events. Millions of people safely take dietary supplements
every day.44 But just because a dietary supplement is not dangerous does
not mean that the dietary supplement has any actual value to maintaining
health. Some of the most popular vitamins and minerals used today have
recently had their efficacy called into question.
Initial tests and studies of vitamins suggested that they may help prevent
cancer, stroke, and heart disease.45 In 2008, after the investment of
hundreds of millions of dollars in clinical trials to further understand the
capabilities of popular vitamins and minerals, two large trials failed to prove
that vitamin C and vitamin E reduce the risk of certain cancers.46 However,
the results of the clinical trials do not mean that vitamin C and vitamin E are
worthless. Vitamins may serve other important functions, as “[s]cientists
remain convinced that vitamins are essential to health.”47 Further, the bad
publicity surrounding the recent results of the clinical trials on vitamins may
not be as significant for consumers as people may think. Many American
consumers believe that dietary supplements can lead to better health,48
including data that suggests that fifty-seven percent of regular dietary
supplement users in 1999 believed dietary supplement claims in
advertisements generally were true.49 At the same time, only fifty-three
percent of respondents to a different 1999 survey were aware that dietary
supplements were not heavily regulated by the government.50

42. 10 Years After the Implementation of DSHEA: The Status of Dietary Supplements in
the United States: Hearings Before the Subcomm. on Hum. Rights and Wellness, 108th Cong.
8-9 (2004) [hereinafter Subcomm. on Human Rights] (testimony of Annette Dickinson,
President of the Council for Responsible Nutrition).
43. Id.
44. See Council for Responsible Nutrition, supra note 3.
45. See Karen Kaplan, Vitamins Aren’t a Cure-All, L.A. TIMES, Dec. 21, 2008, at A1.
46. See id. “This month, two long-term trials with more than 50,000 participants offered
fresh evidence that vitamin C, vitamin E and selenium supplements don’t reduce the risk of
prostate, colorectal, lung, bladder or pancreatic cancer.” Id.
47. Id.
48. Robert J. Blendon et al., Americans’ Views on the Use and Regulation of Dietary
Supplements, 161 ARCHIVES INTERNAL MED. 805, 806-07 (2001).
49. Id. at 808.
50. Id.
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Consumers may also be unaware that certain popular dietary
supplements may be dangerous when combined with prescription drugs or
over-the-counter medications. “Vitamins A, B6, B12, C, E and K; niacin;
folic acid; calcium; magnesium; iron; and zinc can be hazardous when
combined with various prescription drugs and over-the-counter remedies.
Yet patients often fail to mention using such supplements to physicians.”51
Even more worrisome, almost seventy percent of older adults who regularly
take a prescription medication also take an over-the-counter medication,
dietary supplement, or both.52 But data suggests that it may be difficult to
discourage consumers from taking their favorite supplements. Studies show
that seventy-one percent of regular users of dietary supplements claimed
that they would continue to take their most-used supplement even if a
government agency told them the supplement was ineffective.53
III. DIETARY SUPPLEMENT REGULATIONS IN THE UNITED STATES AND ABROAD

A. Regulations in the United States
1. Dietary Supplement Health and Education Act
Before DSHEA, the Food Drug & Cosmetic Act (FDCA) regulated dietary
supplements as either foods or drugs because there still was no category for
dietary supplements.54 The FDCA created food standards and mandated
pre-market approval for all new drugs, but lumped vitamins, minerals, and
herbs together as foods.55 Consequently, such substances received little
regulation.56 Food and drug regulations developed over time, but it took
until the 1990s for Congress to address the expanding market for dietary
supplements by creating regulations specific to the dietary supplement
industry.
By the early 1990s, Congress focused its attention on legislation to
address the questionable health claims made on nutritional product labels.57
Two bills were considered: “One proposal would have strengthened the
FDA’s enforcement powers and increased penalties for violating the [FDCA].

51. Jane E. Brody, Potential for Harm in Dietary Supplements, N.Y. TIMES, Apr. 8, 2008,
at F7.
52. Roni Caryn Rabin, Seniors Mixing Prescription and O.T.C. Drugs, N.Y. TIMES, Jan. 8,
2009, http://www.nytimes.com/2009/01/09/health/08seniors.html.
53. Blendon, supra note 48, at 807.
54. See Peter Barton Hutt, FDA Statutory Authority to Regulate the Safety of Dietary
Supplements, 31 AM. J.L. & MED. 155, 155 (2005).
55. Id. at 156.
56. Id.
57. See Peter J. Cohen, Science, Politics, and the Regulation of Dietary Supplements: It’s
Time to Repeal DSHEA, 31 AM. J.L. & MED. 175, 179 (2005).
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The other would have imposed tight controls on the marketing of nutritional
supplements by forbidding manufacturers to advertise therapeutic claims
that, by law, could not be placed on the supplement’s label.”58 In response
to potential regulations that would regulate vitamins and other supplements,
the health-food industry mounted a massive lobbying campaign.59 “A
coalition composed of health food stores, supplement users, the supplement
industry, lobbyists, and sympathetic members of Congress created a new
class of products and simultaneously declared that this new class would not
be subject to the mission of the FDA.”60 Senator Orrin Hatch (R-UT)
spearheaded the campaign and the Dietary Supplement Health and
Education Act (DSHEA) of 1994 was signed into law by President Bill
Clinton.61 “As a result, the necessary controls that the FDA was legally able
to exert over prescription products were completely invalidated for dietary
supplements . . . .”62
DSHEA provides dietary supplements with their own specific regulatory
framework, but the level of regulation DSHEA created over the dietary
supplement industry is weak.63 Viewed optimistically, “[DSHEA] was passed
in 1994 for two primary reasons: to ensure that consumers would continue
to have access to a wide variety of safe dietary supplements and to provide
consumers with more information about the dietary supplements they
purchase.”64 However, such a statement is far too simplistic for the reach,
or lack thereof, of the Act.
Specifically, DSHEA classifies a dietary supplement as a product other
than tobacco that is intended to supplement the diet; contains one or more
dietary ingredients (including vitamins, minerals, herbs or other botanicals,
amino acids, and other substances, concentrates, metabolites, constituents,
extracts, or combinations of these ingredients); is intended for ingestion in
powder, softgel, gelcap, capsule, tablet, or liquid form; is not represented
for use as a conventional food or as the sole item of a meal or diet; and is

58. Id.
59. Id.
60. W. Steven Pray, Consult Your Pharmacist: The FDA, Vitamins, and the Dietary
Supplement Industry, U.S. PHARMACIST, Oct. 2008, at 15.
61. Id.
62. Id.
63. See Michael H. Cohen, U.S. Dietary Supplement Regulation: Belief Systems and Legal
Rules, 11 HASTINGS WOMEN’S L.J. 3, 4 (2000) (“DSHEA reaffirms that dietary supplements are
‘foods’ and not ‘drugs,’ thus exempting dietary supplements from the requirement of new drug
approval under the Federal Food, Drug & Cosmetic Act (FDCA). A ‘drug’ includes, among
other things, ‘articles intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease.’”).
64. Subcomm. on Human Rights, supra note 42, at 2.
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labeled as a dietary supplement.65 These products can be purchased in a
wide variety of stores throughout the country. “Dietary supplements are the
most commonly used of all complementary and alternative therapies,
primarily because they are widely available and can be bought without
consulting a professional health practitioner.”66
Although the definition of a dietary supplement is liberal, there is an
important distinction between traditional dietary supplements and new
dietary supplements. Dietary ingredients on the market prior to October 15,
1994 were “grandfathered” into the regulations, allowing for their default
marketing and sale.67 Therefore, dietary supplement manufacturers are
allowed to continue to develop and market these “traditional” dietary
supplements as they had before the passage of DSHEA. New dietary
ingredients, those not marketed in the United States before October 15,
1994,68 face some specific hurdles. New dietary ingredients may be
allowed to be a part of a dietary supplement only if they
have been present in the food supply as an article used for food in a form in
which the food has not been chemically altered[or] [t]here is a history of use
or other evidence of safety establishing that the dietary ingredient when used
under the conditions recommended . . . will reasonably be expected to be
safe . . . .69

In order to bring new dietary ingredients to market, companies are required
to notify the FDA about any new ingredient that the companies plan to
Such
market at least seventy-five days before actual marketing.70
notifications must provide a basis for the FDA to determine whether or not
the new dietary ingredient is reasonably expected to be safe.71
Another important regulatory element developed by DSHEA concerns
the restrictions upon the types of claims dietary supplements can make.
“Claims that can be used on food and dietary supplement labels fall into
three categories: health claims, nutrient content claims, and
structure/function claims.”72 Manufacturers and the FDA are responsible for
ensuring the legitimacy of the claims made on dietary supplement labels,

65. 21 U.S.C. §§ 321(ff)(1)-(2) (2006); id. § 350(c)(1)(B)(ii).
66. MERCK MANUAL, supra note 28, at 2724.
67. 21 U.S.C. § 350b(c).
68. Id.
69. Id. § 350b(a)(1)-(2).
70. Id. § 350b(a)(2).
71. Id.
72. U.S. Food & Drug Admin., Claims That Can Be Made for Conventional Foods and
Dietary Supplements (2003), http://www.fda.gov/Food/LabelingNutrition/Label Claims/ucm
111447.htm [hereinafter Supplement Claims].
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while the Federal Trade Commission is responsible for the regulation of
product advertising.73
Health claims are considered claims that describe the relationship
between the product and a reduction in the risk of a disease or healthrelated condition.74 As opposed to claims that the dietary supplement may
help prevent a condition, a dietary supplement “may not claim to diagnose,
mitigate, treat, cure, or prevent a specific disease or class of diseases.”75
An example of a permissible health claim for a dietary supplement could be:
“Diets high in calcium may reduce the risk of osteoporosis.”76
Nutrient content claims are different. “Nutrient content claims describe
the level of a nutrient or dietary substance in the product, using terms such
as free, high, and low, or they compare the level of a nutrient in a food to
that of another food, using terms such as more, reduced, and lite.”77
Nutrient content claims typically only apply to dietary substances with
recognized daily values recommendations.78 An example of a nutrient
content claim could be: “Twice the omega-3 fatty acids per capsule (80 mg)
as in 100 mg of menhaden oil (40 mg).”79
Dietary supplement manufacturers may also describe the supplement’s
effects on “structure or function” of the body or the “well-being” achieved
through consumption of the supplement.80 Structure/function is understood
“to refer to food label statements that describe the role of a nutrient or other
dietary supplement ingredient in maintaining normal structure or function in
humans (e.g. calcium builds strong bones) or to promote general wellbeing.”81 As opposed to actual health claims, structure/function claims may
not state or otherwise imply any relationship between the product and a
disease or health condition.82 However, a structure/function claim may
relate to a disease or health condition if the claim expresses how
widespread the disease is in the United States.83

73. Id.
74. Id. (noting that the FDA regulates health claims through the 1990 Nutrition Labeling
and Education Act (NLEA), the 1997 Food and Drug Administration Modernization Act
(FDAMA), and the 2003 FDA Consumer Health Information for Better Nutrition Initiative).
75. 21 U.S.C. § 343(r)(6)(C).
76. Supplement Claims, supra note 72.
77. Id.
78. Id.
79. Id.
80. 21 U.S.C. § 343(r)(6)(A) (2006).
81. James E. Hoadley & J. Craig Rowlands, FDA Perspectives on Food Label Claims in
the USA, in NUTRACEUTICAL AND FUNCTIONAL FOOD REGULATIONS IN THE UNITED STATES AND
AROUND THE WORLD 115, 128 (Debasis Bagchi ed., 2008).
82. Id. at 128-29.
83. Id. at 129.
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Regardless of the category the claim falls into, it is necessary for the
manufacturer to have “substantiation that such statement is truthful and not
misleading . . . .”84 Also, the product label must include: “This statement
has not been evaluated by the Food and Drug Administration. This product
is not intended to diagnose, treat, cure, or prevent any disease.”85
Finally, as previously noted the most controversial declaration DSHEA
makes concerns the burden of proof for product safety. Under DSHEA,
dietary supplement manufacturers do not have to prove to the FDA that their
product is either safe or effective before marketing or sale of that product.86
The burden of proof in showing the safety of a dietary supplement was
removed from the responsibilities of the manufacturer and shifted to the
FDA.87
In the last few years, dietary supplement regulation has consequently
expanded to include new regulations that focus upon adverse event reports
and good manufacturing practices.
2. The Dietary Supplement and Non-prescription Drug Consumer
Protection Act
In order to monitor health problems associated with the use of
pharmaceuticals and therapeutic biological products, the FDA relies on the
compilation of adverse event reports.88 Adverse event reports are most well
known for their application to pharmaceuticals. “The Adverse Event
Reporting System (AERS) is a computerized information database designed
to support the FDA’s post-marketing safety surveillance program for all
approved drug and therapeutic biologic products.”89
When DSHEA was first passed, DSHEA notably did not contain a
mandatory reporting requirement for adverse events related to dietary
supplements. However, apparently due to public outrage over the slow
development of information and reaction related to the ephedra deaths,
Senator Orrin Hatch (R-UT), along with Senators John Cornyn (R-TX),
Richard Durbin (D-IL), Michael Enzi (R-WY), Thomas Harkin (D-IA), and
Edward Kennedy (D-MA) introduced the Dietary Supplement and

84. 21 U.S.C. § 343(r)(6)(B) (2006).
85. Id. § 343(r)(6)(C).
86. Id. § 342(f).
87. Id.
88. FDA.gov, Adverse Event Reporting System (AERS), http://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm (last
visited Nov. 21, 2009).
89. Id.
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Nonprescription Drug Consumer Protection Act (DSNDCPA).90
The
DSNDCPA was signed into law by President Bush on December 22, 2006
and came into effect on December 22, 2007.91
The DSNDCPA attempts to improve consumer protection by requiring
manufacturers to report adverse events.92
The manufacturer, packer, or distributor of a dietary supplement whose
name . . . appears on the label of a dietary supplement marketed in the
United States . . . [is required to] submit to the Secretary any report received
of a serious adverse event associated with such dietary supplement when
used in the United States, accompanied by a copy of the label on or within
the retail packaging of such dietary supplement.93

The act classifies a “serious adverse event” as an “adverse event that
results in death; a life-threatening experience; inpatient hospitalization; a
persistent or significant disability or incapacity; or a congenital anomaly or
birth defect; or requires, based on reasonable medical judgment, a medical
or surgical intervention to prevent an outcome described [above].”94 The
FDA evaluates the adverse event reports and determines whether or not
regulatory action is necessary.95
In September 2008, the FDA lowered its cumulative 2008 estimate for
the total number of expected adverse event reports potentially related to
dietary supplements from 960 to 856.96 For the first quarter of 2008, the
FDA received a total of 214 mandatory reports of serious adverse events
related to dietary supplements.97 However, it is estimated that the actual
number of all adverse events relating to dietary supplements may be more
than 50,000 per year.98

90. GovTrack.us, S. 3546: Dietary Supplement and Nonprescription Drug Consumer
Protection Act, http://www.govtrack.us/congress/bill.xpd?bill=s109-3546 (last visited Nov.
21, 2009).
91. 21 U.S.C. § 379aa-1(i).
92. Id. § 379aa-1(b)(1).
93. Id. § 379aa-1(b)(1).
94. Id. § 379aa-1(a)(2).
95. See FDA.gov, supra note 88 (stating in reference to the AERS system for drugs,
“Based on an evaluation of the potential safety concern, FDA may take regulatory action(s) to
improve product safety and protect the public health, such as updating a product’s labeling
information, restricting the use of the drug, communicating new safety information to the
public, or, in rare cases, removing a product from the market”).
96. Notice: Adverse Event Reporting and Recordkeeping for Dietary Supplements as
Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act, 73
Fed. Reg. 53253 (Sept. 15, 2008).
97. Id.
98. Id. at 53254.
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Importantly, an adverse event does not necessarily signify the existence
of a causal relationship.99 Some adverse events may be reported by people
who already were ill and had been using either over-the-counter or
prescription drugs at the time of the adverse event.100 Regardless, the FDA
is required by law to investigate serious adverse events and subsequently
determine whether or not the dietary supplement is the cause of the adverse
event.101
3. Dietary Supplement Good Manufacturing Practices Final Rule
Another important rule recently developed for the dietary supplement
industry concerns the creation and implementation of standards for the
manufacturing of dietary supplements. The pharmaceutical industry has
required drug manufacturers to follow current good manufacturing practices
(CGMPs) since they were adopted in 1963.102 In 2007, the FDA finalized
CGMPs for the dietary supplement industry.103 As Janice Oliver, Deputy
Director of the Center for Food Safety and Applied Nutrition explains,
[t]he dietary supplement market has changed significantly since the passage
of DSHEA. The industry itself has grown exponentially and so has the
number of Americans buying these products. Access to dietary supplements
has also changed. Today a wide range of dietary supplements can be
purchased in supermarkets or through the Internet. The dynamic nature of
this industry underscores the importance of and the necessity for Good
Manufacturing Practice requirements for dietary supplements.104

Given authority under DSHEA, the FDA published its proposed rule on
CGMPs in 2003105 and the Final Rule was adopted June 25, 2007.106 The
Final Rule creates the minimum CGMPs for dietary supplement
99. Natural Products Association, FDA Reports Lower Supplement AERs than Expected
(Sept. 24, 2008), http://www.npicenter.com/anm/templates/newsATemp.aspx?articleid=222
20&zoneid=2.
100. Id.
101. Id.
102. Current Good Manufacturing Practice in Manufacture, Processing, Packing, or
Holding, 28 Fed. Reg. 6385, 6385 (June 20, 1963).
103. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 21 C.F.R. § 111 (2007).
104. Janice Oliver, Deputy Director, Center for Food Safety and Applied Nutrition,
Overview of the Implementation of the Current Good Manufacturing Practices for Dietary
Supplements Guidance for Industry, FDA Satellite Broadcast (Oct. 24, 2007), http://www.fda.
gov/Food/DietarySupplements/GuidanceComplianceRegulatoryInformation/RegulationsLaws/
ucm173996.htm.
105. Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary
Ingredients and Dietary Supplements, 68 Fed. Reg. 12158, 12158 (proposed Mar. 13, 2003)
(codified at 21 C.F.R. pt. 111).
106. 21 C.F.R. § 111 (2007).
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manufacturing, packaging, labeling, or holding.107
Prior to the
implementation of the recent Final Rule, dietary supplements were subject to
the same manufacturing practice requirements as conventional foods.108
The CGMPs provide requirements for the quality production of dietary
supplements and ensures that the products are labeled properly and do not
contain contaminants or impurities.109 The goal is to provide consumer
confidence that the dietary supplements on the market have been
manufactured to ensure their identity, purity, strength, and composition.110
The FDA Commissioner Andrew Von Eschenbach remarked that “[t]his rule
helps to ensure the quality of dietary supplements so that consumers can be
confident that the products they purchase contain what is on the label.”111 If
there is evidence of contaminants or the dietary supplements do not contain
the dietary ingredients that they claim, then the FDA considers those
supplements to be adulterated or misbranded and subject to regulatory
action.112 However, it is important to note that the CGMPs do not require
any proof of efficacy.
The FDA estimates that there are 1,460 manufacturers, packers, and
holders of dietary supplements.113 Depending on the size of the business,
there is a specific date when the CGMPs take effect.114 For businesses with
500 employees or more, the effective compliance date was June 25,
2008.115 For businesses with 20–499 employees, the effective compliance
date was June 25, 2009; and for businesses with fewer than twenty
employees, the effective compliance date is June 25, 2010.116

107. 21 C.F.R. § 111 (2007); Current Good Manufacturing Practice in Manufacturing,
Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752
(June 25, 2007).
108. Subcomm. on Human Rights, supra note 42, at 5.
109. See 21 C.F.R. § 111 (2007); Press Release, FDA, FDA Issues Dietary Supplements
Final Rule (June 22, 2007), http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce
ments/2007/ucm108938.htm.
110. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 72 Fed. Reg. at 34761.
111. Julia Sommerfeld, Dietary Supplements Face Stricter Regulations: For First Time,
Companies Must Test Products for Contamination, FDA Says, MSNBC.COM, June 22, 2007,
http://www.msnbc.msn.com/id/19370824/.
112. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 72 Fed. Reg. at 34762-64; Press Release, supra
note 109.
113. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752, 34920 (June 25, 2007).
114. Id. at 34752.
115. Id.
116. Id.
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Regulations in other Countries

Dietary supplements are not only popular in the U.S., but around the
world consumers, manufacturers, and regulatory bodies have started to see
the effects of an emerging and continually expanding market for dietary
supplements.117 As one industry manager wrote in 2008, “[g]lobal demand
for dietary and nutritional supplements continues to escalate—steadily in
mature major markets and exponentially in smaller emerging markets.”118
With demand for dietary supplements increasing, regulatory bodies have
tried to keep pace in covering these products. Some countries regulate
dietary supplements with specific laws and regulations, while others regulate
dietary supplements by categorizing them as either foods or drugs. In order
to analyze different regulatory approaches to dietary supplements, this
section looks at dietary supplement regulations in large, developed dietary
supplement markets outside of the U.S., with specific focus on regulations in
the European Union, Japan, Canada, and Australia.
1. Dietary Supplement Regulation in the European Union
In 2007, Japan, the United States, and the EU represented roughly
eighty-six percent of the global dietary supplement market.119 Dietary
supplement regulation in the EU is grounded in Directive 2002/46/EC (the
Food Supplements Directive), adopted June 10, 2002.120 The Food
Supplements Directive was created as a comprehensive regulatory
framework to resolve previous issues concerning the multiple regulatory
bodies of the different member countries of the EU.121 Different national
rules for dietary supplements “may impede their free movement, create
unequal conditions of competition, and thus have a direct impact on the
functioning of the internal market.”122 Therefore, regulation across the
European Union is necessary.123
The Food Supplements Directive specifies which food supplements may
be sold in the European Union, using two different annexes—also known as
the “positive list.”124 Since August 1, 2005, manufacturers, distributors, and
117. See Charles Thurston, Dietary Supplements: The Latest Trends & Issues,
NUTRACEUTICALS WORLD, Apr. 2008, at 54.
118. Zambetti, supra note 6.
119. Thurston, supra note 117, at 54.
120. Council Directive 2002/46, On the Approximation of the Laws of the Member States
Relating to Food Supplements, 2002 O.J. (L 183) 51, 51 (EC).
121. Id.
122. Id.
123. Id.
124. Id. at 51, 52.
‘[F]ood supplements’ means foodstuffs the purpose of which is to supplement the
normal diet and which are concentrated sources of nutrients or other substances with a
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retailers of food supplements in Europe are prohibited from selling food
supplements not listed on the positive list.125 As written, the positive list
includes only thirteen vitamins in thirty-two possible forms, and fifteen
minerals in eighty possible forms.126 If an EU member state wants to allow
use of vitamins and minerals not included on the positive list, the state may
do so until December 31, 2009 provided: 1) the substance was already in a
supplement marketed in the state at the time of the adoption of the directive,
and 2) the European Food Safety Authority has not given an unfavorable
opinion of that substance based upon a dossier supporting the use of that
substance.127
For nutritional supplements on the market, the Food Supplements
Directive contains requirements for the labeling of food supplements. Labels
of food supplements must contain: the term “food supplement”, the names
of the categories of substances that characterize the product, the
recommended daily portion of that supplement, a warning to not exceed the
recommended daily portion, a statement that the supplement is not a
substitute for a varied diet, and a warning that the product should be stored
out of the reach of young children.128 Likewise, there are prohibited
statements. The food supplement label must not contain any statement that
the product is capable of preventing, treating, or curing a human disease,
or any statement or implication that a balanced diet cannot provide
adequate amounts of the nutrients.129
The Food Supplements Directive was met with massive opposition in
Europe over the loss of consumer choice for certain products. “The plans
caused controversy from the start, prompting a petition of more than a
million signatures, a letter of protest to Tony Blair from more than 300
doctors and scientists, and motions opposing the law in both Houses of

nutritional or physiological effect, alone or in combination, marketed in dose form,
namely forms such as capsules, pastilles, tablets, pills and other similar forms, sachets
of powder, ampoules of liquids, drop dispensing bottles, and other similar forms of
liquids and powders designed to be taken in measured small unit quantities.
Id. at art. 2. Annex I provides the vitamins and minerals that are allowed, and Annex II
provides the forms of those vitamins and minerals that may be used for the manufacture of
food supplements. Id. at art. 4.
125. See Council Directive 2002/46, art. 15, 2002 O.J. (L 183) 51, 55 (EC).
126. Id. at 55, 56.
127. Id. at art. 4 (noting that the deadline for submitting a dossier for consideration was
July 12, 2005); Christine Eberhardie, Nutritional Supplements and the EU: Is Anyone Happy?,
66 PROC. NUTRITION SOC’Y 508, 509 (2007) (noting that the application requirement had
already resulted in applications for 421 substances).
128. See Council Directive 2002/46, art. 6, 2002 O.J. (L 183) 51, 55 (EC).
129. Id. at art. 6, 7.
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Parliament.”130 In July, 2005, the European Court of Justice upheld the
application of the Food Supplements Directive, effectively striking down an
appeal from the health food industry challenging its legality.131 In the
comparatively large supplement market of the UK, the Directive will ban
roughly 300 forms of vitamins and minerals unless they are included on the
positive list.132 Consumers consequently lost access to vitamins and
minerals previously sold in the EU for many years.133
2. Dietary Supplement Regulation in Japan
Japan is another very important member of the dietary supplement
industry. As noted above, in 2007, Japan, the United States, and the EU
represented roughly eighty-six percent of the global dietary supplement
market.134 Dietary supplement regulation in Japan exists under a complex
system of regulations that have developed and changed over time, but there
still are no specific regulations or even a specific term for dietary
supplements.135 Due to the complexity of the regulations that cover dietary
supplements, it “may often make it difficult to comprehend the Japanese
regulatory system of [health foods] for the food industry in foreign
countries.”136
In Japan, foods and drugs are regulated by the Japanese Ministry of
Health, Labor and Welfare (MHLW).137 Since Japan does not specifically
address dietary supplements in a statutory framework, dietary supplements
instead fall under a network of food and drug regulations that have
developed and changed multiple times within the last few years.138 In 1991,
‘health foods’ (which are roughly analogous to dietary supplements in the

130. Sam Lister, Health Groups Lose Appeal on EU Food Supplement Ban, TIMES (London),
July 13, 2005, at 14.
131. Id.
132. Id.
133. Id. (noting that the ‘positive list’ includes and allows the sale of vitamin C, calcium,
and iron, but other “popular substances, such as selenium yeast, tin, manganese and vitamin
K2, have been omitted and are subject to 505 separate appeals”).
134. Thurston, supra note 117, at 54; see Hirobumi Ohama et al., Health Foods and
Foods with Health Claims in Japan, in NUTRACEUTICAL AND FUNCTIONAL FOOD REGULATIONS IN
THE UNITED STATES AND AROUND THE WORLD 249, 275 (Debasis Bagchi ed., 2008) (noting that
Japan’s market for dietary supplements is “almost equivalent to the EU market” while
accounting for $12.1 billion in 2006).
135. See Ohama et al., supra note 134, at 252.
136. Id.
137. See Paul Yamaguchi, Japan’s Nutraceuticals Today – A Big Disappointment in FoodDrug Reclassification: Expectations Are Not Always Realized (Apr. 16, 2007),
http://www.npicenter.com/anm/templates/newsATemp.aspx?articleid=18281&zoneid=45.
138. See id. (noting that food and drug reclassifications have been conducted “almost
once a year, but over the last 3 years the agency still hasn’t completed one”).
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U.S.) were integrated into the “Foods for Specified Health Uses” (FOSHU)
system.139 “The Japanese government developed FOSHU to identify
conventional foods that positively contribute to physiological systems in the
human body from other foods by allowing these foods to have health claims
and an approved logo printed on their package.”140 Substances that are
considered dietary supplements in the U.S. would fall under either the drug
regulations or the non-drug food regulations, depending on many different
factors.141 “Many ingredients in the U.S. are still tightly guarded under
Japan’s Pharmaceutical Affair Law. They can’t be formulated into foods or
supplements.”142
Japanese food and drug regulations are strict and have prohibited open
trade of dietary supplements between Japan and the U.S., resulting in
requests to deregulate the ‘health food’ system and re-classify ingredients.143
‘Reclassification’ can be understood as the process where the MHLW takes
a product out from under drug regulations, and moves it under non-drug
regulations.144 Once the MHLW allows an ingredient to move to a nondrug status, the ingredient may be used as a supplement.145 Since 2001,
the MHLW has reclassified a list of ingredients every few years.146 In 2007,
MHLW released its fourth food-drug reclassification, which included fifty-five
ingredients.147 Also of significant importance and seen as a sign of
progress, in 2007 the MHLW for the first time announced that it intends to
allow a public hearing concerning the products to be placed on the next
reclassification list.148
However, the nutritional industry in Japan still “needs a boost every few
years in order to grow.”149 The downturn in the Japanese economy hit the

139. Paul Yamaguchi, Japan’s Nutraceuticals Today – FOSHU Ready to Change – Again
(June 26, 2004), http://www.npicenter.com/anm/templates/newsATemp.aspx?articleid=104
57&zoneid=45.
140. Id.
141. See Ohama et al., supra note 134, at 253, 257-58.
142. See Yamaguchi, supra note 137.
143. See Ohama et al., supra note 134, at 252 (noting that prior to 2001, “only the form
of conventional foods was permitted while other forms such as tablets or capsules were not
allowed”).
144. See Yamaguchi, supra note 137.
145. Id. (noting that in 2002, the supplement “CoQ 10 moved to non-drug status and the
market grew from almost zero to $100 million in two short years”).
146. See id.
147. See id. Categories include botanical, animal, and chemical ingredients. Out of the
55 ingredients reclassified, 33 were botanicals and only one was a chemical (L-citruline). Id.
148. See id.
149. Paul Yamaguchi, Japan’s Nutraceuticals Today – Japan’s Economic Recovery Leaves
Nutrition Industry Behind (Oct. 9, 2007), http://www.npicenter.com/anm/templates/news
ATemp.aspx?articleid=19613&zoneid=45.
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nutritional industry hard in 2006, and the nutrition market contracted for the
first time in its history.150 But the economy is not the only factor to blame.
“The Japanese nutrition industry, especially the nutritional supplement
category, is still fragile and unsettled because of the lack of nutritional
supplement laws. Until the laws that recognize supplements are written, the
Japanese nutritional supplement market will remain unsettled.”151
3. Dietary Supplement Regulation in Canada
In Canada, dietary supplements are known as natural health products
(NHP), defined under the Natural Health Product Regulations. Like
Americans, Canadians have become heavy users of dietary supplements, as
studies have shown that seventy percent of Canadians consume one or
more natural health products.152 In 2006, it was estimated that the
Canadian health products industry was worth $2.5 billion.153
The Natural Health Products Directorate (NHPD), under the Health
Products and Food Branch of Health Canada, acts as the regulatory
authority for natural health products in Canada.154 Like the American
system, dietary supplement products do not fit within the regulatory
framework for pharmaceuticals, nor do they fit within the regulatory
framework for foods.155 But in stark contrast to the American regulatory
framework, the NHP Regulations require that NHPs obtain a product license
through pre-market approval by the Minister of Health.156 The NHP
Regulations place requirements upon manufacturers, distributors, importers,
packagers, and labelers.157 As the Regulatory Impact Analysis Statement
reports, “[t]hese Regulations are intended to provide Canadians with ready
access to natural health products that are safe, effective, and of high quality,
while respecting freedom of choice and philosophical and cultural
diversity.”158
150. Id. (reporting that the Japanese nutrition market has averaged twelve percent annual
growth over the last twenty years, but in 2006 the fell two percent).
151. Id.
152. CANADIAN HEALTH FOOD ASSOCIATION, supra note 5.
153. Id.
154. Regulatory Impact Analysis Statement of the Natural Health Products Regulations,
137 C. GAZ. PART II, NO. 13 at 1571 (June 18, 2003) [hereinafter Regulatory Impact Analysis
Statement] (the Regulatory Impact Analysis Statement is not part of the Natural Health
Products Regulations).
155. Id. at 1592-93 (noting that “[i]t was decided the most effective regulatory mechanism
was to create a new set of Regulations specific to NHPs . . .”).
156. Natural Health Products Regulations SOR/2003-196, s. 4(1) (Can). An application
for a product license requires specific information such as the recommended purpose of the
NHP and supporting safety and efficacy data. Id. at s. 5.
157. Id. at s. 2(1).
158. Regulatory Impact Analysis Statement, supra note 154, at 1571.
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The NHP Regulations provide a regulatory structure for an estimated
40,000 supplement products and traditional and alternative medicines.159
NHPs include homeopathic and traditional medicines,160 as well as plants,
fungi, vitamins, amino acids, essential fatty acids, minerals, and
probiotics.161 NHPs must be safe enough to be considered for over-thecounter use and must not require a prescription to be sold.162 Products that
do require prescriptions are regulated under the Food and Drug
Regulations.163 Once pre-market approval is given, NHPs can make “a full
range of health claims, including structure-function, risk-reduction, and
therapeutic or treatment claims.164
To be considered an NHP, the product must have both a function
component and a substance component.165 The function component covers
substances which are
manufactured, sold or represented for use in: the diagnosis, treatment,
mitigation or prevention of a disease, disorder, or abnormal physical state
or its symptoms in humans[;] restoring or correcting organic functions in
humans; or modifying organic functions in humans, such as modifying those
functions in a manner that maintains or promotes health.166

The substance component is the medicinal ingredient of the product (which
includes, among others, vitamins, minerals, and amino acids).167 NHP
Regulations are mainly comprised of regulations pertaining to “definitions,
product licensing, adverse reaction reporting, site licensing, good
manufacturing practices, clinical trials involving human subjects, and
labelling [sic] [and] packaging.”168
Like American dietary supplement regulations, Canadians have adopted
good manufacturing practices for NHPs.169 Canada also utilizes mandatory

159. Stephanie Martyres et al., Emerging Policies and Practices Under the Canadian
Natural Health Product Regulations, in NUTRACEUTICAL AND FUNCTIONAL FOOD REGULATIONS IN
THE UNITED STATES AND AROUND THE WORLD

159, 160 (Debasis Bagchi ed., 2008).
160. Regulatory Impact Analysis Statement, supra note 154, at 1574.
161. Natural Health Products Regulations SOR/2003-196, Schedule 1 (Can).
162. See id. at s. 2(2); see also Regulatory Impact Analysis Statement of the Natural Health
Products Regulations, supra note 154, at 1572.
163. Natural Health Products Regulations SOR/2003-196, s. 2(2) (Can).
164. See Regulatory Impact Analysis Statement, supra note 154, at 1574.
165. Id. at 1573.
166. Id.
167. Id. at 1574-76.
168. Id. at 1578.
169. HEALTH CAN., NATURAL HEALTH PRODUCTS DIRECTORATE, GOOD MANUFACTURING
PRACTICES GUIDANCE DOCUMENT i (2006), available at http://hc-sc.gc.ca/dhp-mps/alt_
formats/hpfb-dgpsa/pdf/prodnatur/gmp-bpf-eng.pdf.
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adverse event reporting systems.170 The licensee or product license holder
of a natural health product in Canada is required to report to Health
Canada any adverse reactions that are associated with the use of its
licensed natural health product.171 The licensee is required to develop and
maintain procedures to properly collect information about adverse event
reports, prepare and submit to Health Canada adverse reaction reports,
and respond fully and promptly to Health Canada for additional safety
information.172
Critics of the NHP Regulations claim that the pre-market approval
system is difficult on smaller companies due to the cost of compliance for
product licensing.173 Critics also find that the costs of complying with the
mandatory GMPs weaken incentives to create new products.174 Finally,
industry members have been highly frustrated with the delay between
applying for product approval and actual approval or denial.175
Accordingly, “[t]he current regulatory environment has left everyone
frustrated at the promise of the new regulations not being met.”176
4. Dietary Supplement Regulation in Australia
Australia does not contribute to a large portion of the global dietary
supplement industry in terms of consumer sales, but it still provides an
interesting regulatory framework for dietary supplements. Australia and
New Zealand share one framework for the regulation of foods, the Australia
New Zealand Food Standards Code, but they do not agree on the
regulation of dietary supplements or medicines.177 In Australia, the line is
drawn between whether the ingested product is a food or a medicine—there
is no classification for dietary supplements—while in New Zealand, dietary
170. HEALTH CAN., CANADA VIGILANCE PROGRAM, GUIDANCE DOCUMENT FOR INDUSTRY –
REPORTING ADVERSE REACTIONS TO MARKETED HEALTH PRODUCTS 1 (2009), available at
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/2009_guidancedirectrice_reporting-notification-eng.pdf (An adverse reaction is “a noxious and unintended
response to a natural health product that occurs at any dose used or tested for the diagnosis,
treatment or prevention of a disease or for modifying an organic function”). Id. at 2.
171. Id. at 4, 7.
172. See id. at 7-9.
173. See Bill Reynolds, Canada Prepares for New Supplement Regs,
NATURALPRODUCTSINSIDER.COM (July 29, 2002), http://www.naturalproductsinsider.com/
articles/2002/07/canada-prepares-for-new-supplement-regs.aspx.
174. Id.
175. Len Monheit, Canada: The Status of Natural Health Product Regulations,
NUTRACEUTICALS WORLD, July–Aug. 2006, at 42, 44.
176. Id.
177. Jane L. Allen et al., Functional Foods: Australia/New Zealand, in REGULATION OF
FUNCTIONAL FOODS AND NUTRACEUTICALS: A GLOBAL PERSPECTIVE 321, 321 (Clare M. Hasler
ed., 2005).
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supplements comprise their own specified category apart from food and
medicine.178
Without a specific category for dietary supplements, Australia employs a
blanket approach to regulation. Products such as vitamins, minerals, and
nutritional supplements are regulated as complementary medicines under
the Therapeutic Goods Act of 1989.179 Under the Act, dietary supplements
are regulated equally with other ‘complementary’ medicines,180 allowing for
a “substantially uniform national system of controls over therapeutic
goods . . . .”181 The popularity of complementary medicines in Australia is
signified by the fact that more than half of all Australians have used
complementary medicines at least once, contributing to the estimated $2
billion per year Australian complementary medicine market.182
For all medicines, Australia separates them among different risk
levels.183 “Most complementary medicines, including most vitamin and
mineral supplements are considered to be low risk medicines, as they may
only contain substances that have been approved by the TGA [Therapeutic
Goods Administration] as being of low risk.”184 Through placement in this
low-risk category, these products must be tested for both quality and safety,
but are not required to be tested for effectiveness.185 Further, Australia
requires that these complementary medicine products must conform to
industry GMPs and that adverse event reports be submitted to the TGA.186
However, even with the seemingly strict regulatory control, critics point
out that by not requiring manufacturers to prove efficacy of low-risk

178. Id.
179. Australian Government Department of Health and Ageing, Therapeutic Goods
Administration, The Regulation of Complementary Medicines in Australia – An Overview
(2006), http://www.tga.gov.au/cm/cmreg-aust.htm.
180. Id. Other products that fall under the Australian ‘Complementary Medicines’
category include: herbal medicines, homeopathic medicines, aromatherapy products, and
traditional medicines (which include ayurvedic medicines, traditional Chinese medicines, and
other traditional medicines).
181. Id.
182. The World Today: Complementary Medicine Industry Rejects Calls for Better
Regulation (transcript of ABC radio broadcast June 10, 2008), http://www.abc.net.au/world
today/content/2008/s2270226.htm.
183. Australian Government Department of Health and Ageing, Therapeutic Goods
Administration, Codex Fact Sheet: Proposed Codex Guidelines Will Not Impact on the Way
Vitamin and Mineral Supplements Are Regulated in Australia (2005), http://www.tga.gov.au/
cm/fs_codex.htm (“Australia has a risk-based system where the level of evaluation and
regulatory control of a medicine is based on the relative risk of the product and the
seriousness of the condition for which it is intended to be used.”). Id.
184. Id.
185. Id.
186. Australian Government Department of Health and Ageing, supra note 179.

SAINT LOUIS UNIVERSITY SCHOOL OF LAW

SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY

146

[Vol. 3:123

complementary medicines, consumers do not receive adequate information
about the products and are therefore not protected through current law.187
In response, Dr. Wendy Morrow, the Executive Director of the
Complimentary Healthcare Council disagrees that Australian consumers
need more product information. Dr. Morrow states that the Australian
complementary medicine regulations provide one of the “most scientifically
rigorous
regulatory
frameworks
for
complimentary
medicines
internationally.”188 Dr. Morrow notes that two reviews of the complementary
medicine framework have supported the risk-based regulatory system and
proposed only minor modifications.189

C. Back to the United States: Criticism of DSHEA, DSNDCPA, and CGMPs
With a general understanding of U.S. dietary supplement regulations
and other regulatory structures used around the world, there exists proper
context to look at criticisms of the regulations in the U.S. Like most
controversial topics, criticisms concerning how the US handles dietary
supplement regulations vary across a wide range of perspectives. DSHEA
itself has been targeted with the most disapproval as it is the backbone of
dietary supplement regulation and it has been effective for much longer than
more recent legislation.
1. Criticism of DSHEA
Critics of DSHEA have many different concerns, but only the most
controversial will be discussed here. First and most obvious, critics do not
agree that the burden of proof for safety of dietary supplements should be
the responsibility of the FDA. “A major weakness in DSHEA is that it does
not impose on all dietary supplements the burden and obligation to
affirmatively substantiate their safety.”190 The FDA is a factor only after a
product has already been on the market and it may only remove a dietary
supplement from the market if it proves that the dietary supplement is
adulterated.191 Therefore, the authority of the FDA largely appears to be
reactionary as opposed to preventative, and consequently consumer safety
is put at issue. As L-tryptophan and ephedra have shown, a delay in
assessing the dangers of a product can result in serious harm or even
“DSHEA yielded significant latitude to dietary supplement
death.192

187.
188.
189.
190.

See The World Today, supra note 182.
Id.
Id.
Margaret Gilhooley, Deregulation and the Administrative Role: Looking at Dietary
Supplements, 62 MONT. L. REV. 85, 119 (2001).
191. 21 U.S.C. § 342(f)(1)(D).
192. See FDA INFORMATION PAPER, supra note 12. See also Editorial, supra note 12.
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companies in manufacturing and promoting their products, arguably at the
expense of consumer safety.”193
As noted, the only substantiation claims that DSHEA requires are for
dietary ingredients considered “new” after 1994.194 However, critics claim
that “new” is classified in DSHEA in a narrow fashion that does not require
substantiation for dietary supplements that were used before 1994 for a
different purpose.195 They note that even though the dietary supplement
may have been used prior to 1994, and therefore is “grandfathered” into
protection, new uses of the supplement do not require safety
substantiation.196 Consequently, new uses of the dietary supplement have
no actual proof of consumer safety. Therefore, some propose that if all
dietary supplement manufacturers are required to substantiate the safety of
their products, then the manufacturers would therefore use the necessary
means to assure safety of the products and consumer safety would
theoretically increase.197
The criticisms of DSHEA hold the most weight when looking solely at
DSHEA itself. However, Congress attempted to appease critics with the
passage of the DSNDCPA and the CGMPs.
2. Criticism of the DSNDCPA
While the DSNDCPA is an attempt to improve consumer safety by
requiring dietary supplement manufacturers to report any serious adverse
events to the FDA, it is likely too early to see realistic effects of the legislation
because it only came into effect in December, 2007. Critics, however, have
found multiple areas of contention where the law may fail. Critics argue
that regardless of whether the reporting of adverse events is mandatory or
not, the reporting inherently detects only a small proportion of the events
that are actually due to the dietary supplement.198 This is because it
requires the consumer or a medical professional to actually create the link
between the event and the dietary supplement.199 This criticism may very
well be accurate, but it is an inherent problem when dealing with adverse
events. An adverse event report intrinsically requires someone to make the
determination that there is a link, or a possible link, between a substance or
action and an outcome. Therefore, some adverse events will surely never

193. Michael A. McCann, Dietary Supplement Labeling: Cognitive Biases, Market
Manipulation & Consumer Choice, 31 AM. J.L. & MED. 215, 243 (2005).
194.
195.
196.
197.
198.
199.

21 U.S.C. § 350b(c) (2006).
Gilhooley, supra note 190, at 119.

Id.
Id.
See Wong, supra note 19, at 337.
Id.
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be discovered. The same issue necessarily exists for adverse event reporting
in the pharmaceutical industry, or for that matter, any industry that follows
adverse events.
Critics also argue that some manufacturers may choose to risk
investigation by the FDA rather than to turn over injurious adverse event
reports because of worries about the effects the reports may have on
business.200 However, the criticism that manufacturers will hide injurious
information in order to protect profits is a criticism that can be made
regardless of the law or particular level of regulation. If a manufacturer is
likely to hide injurious information under the rules established by the
DSNDCPA, then there is no evidence whatsoever that those same
manufacturers would not attempt to hide the injurious information if there
were a different law in place.
Finally, critics of the DSNDCPA argue that even if the FDA receives more
adverse event reports, there are still both procedural and economic burdens
that face the FDA. Procedurally, the FDA still bears the burden of proof in
order to show that a dietary supplement or nonprescription drug should be
taken off of the market, and the DSNDCPA does not lighten the FDA’s
burden.201 Economically, the DSNDCPA does nothing to heighten the
priority of dietary supplement or nonprescription drug regulation by the FDA
because doing so would mean more competition for the already strained
resources of the FDA.202 Such criticisms seem valid at this point in time
because the burden of proof that DSHEA created. Until the FDA is allowed
to shift the burden of proof for product safety back to the manufacturer, the
FDA will have to continue to accurately budget expenditures.
3. Criticism of the CGMPs
Critics previously argued that DSHEA does not provide quality standards
for strength and purity and there are no manufacturing standards mandated
by the law.203 However, the CGMPs were created to specifically address this
issue.204 The CGMPs provide specific guidelines for the manufacturing of
dietary supplements.205
Critics argue that the CGMPs do little for product safety. Sidney Wolf,
health director for FDA watchdog group Public Citizen remarked, “[e]ven
with these new manufacturing practices, there will be no assurance that

200. See id.
201. Id. at 337-38.
202. Id. at 338.
203. See RICHARD R. ABOOD, PHARMACY PRACTICE AND THE LAW 48 (2005).
204. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or
Holding Operations for Dietary Supplements, 72 Fed. Reg. 34751, 34752 (June 25, 2007).
205. 21 C.F.R. pt. 111.
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dietary supplements work or are safe.”206 Similar to criticisms regarding the
already-strained resources necessary to investigate adverse event reports,
critics argue that there is a comparable strain on FDA resources for the
enforcement of the CGMPs.207 If there are not enough resources to
implement the law, then it is unlikely that consumers will receive the benefit
of the law’s full potential.208 However, in the same manner, the argument
that resources are too strained for the implementation of the CGMPs is
arguably going to be applicable no matter what the law is because the FDA
still must prioritize the use of resources.
IV. HOW A GLOBAL COMPARISON CAN HELP GUIDE THE UNITED STATES
This note has demonstrated the level of controversy involved in dietary
supplement regulation in the U.S., and how U.S. laws and regulations
compare to those of other dietary supplement markets around the world.
Surprisingly, the largest dietary supplement markets in the world have
drastically different regulatory approaches to dietary supplement products.
On one end of the spectrum, the U.S. supports the largest dietary
supplement market in the world by providing the FDA with a relatively weak
grasp on regulation. However, the DSNDCPA and the CGMPs move
regulation in the direction of a more restricted industry. At the same time,
Japan, Australia, Canada, and the EU are spread out along the continuum,
but mostly remain at the opposite end of the spectrum where dietary
supplements are much more strictly controlled. Importantly, the strict
regulatory control in Japan is moving away from the far end of the spectrum
by allowing more products into the marketplace. By no means are the
regulations in the U.S. and Japan close to meeting in the middle, but they
appear to be slowly heading in from the extremes.
The EU made waves with the Food Supplements Directive by only
allowing the sale of products on the positive list. Consumers and industry
members fought the Food Supplements Directive every step of the way. It is
safe to assume that if the same ‘positive list’ for dietary supplements in the
EU were to be implemented in the U.S., the regulations would be met with
equal, if not much more severe opposition. For example, the health industry
already used its clout to help promote DSHEA from the beginning.209 Surely
a stronger and more politicized health food industry today would not cave
easily into massively-restrictive regulations like the ones in the EU. However,

206. Zwillich, supra note 18.
207. See Rick Liva, New FDA cGMPs for Supplements: Smoke or Substance?, 6
INTEGRATIVE MED. 28, 28 (2007).
208. See id.
209. See Pray, supra note 60, at 15.
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as the EU updates substances for approval on the positive list, it also moves
toward the middle of the regulatory spectrum.
As regulations around the world change, it is important to remember
that the regulation of dietary supplements is very new, and therefore may
require multiple adjustments over time. As one author commenting on a
proposed Canadian natural health product bill said, “[the bill] is just the
next step in this ongoing regulatory development process.”210 In this aspect,
dietary supplement regulations around the world are developing a theme:
regulation of dietary supplements is a process. The U.S. adopted the
DSNDCPA and the CGMPs in the last few years;211 Japan’s MHLW has
changed and updated regulations multiple times since 2001;212 Canada
continues to address new possible regulations as the market changes;213
and the EU passed the Food Supplements Directive in 2002 and is working
towards accepting more supplements onto its positive list.214 Australia,
apparently content to regulate dietary supplements under the blanket
framework for complementary medicines, is currently not considering
amendments to its regulations.215
Even if Congress gave the FDA the authority to control dietary
supplements as strictly as other parts of the world, the FDA would not have
enough funding to undertake the responsibility. In 2007, a subcommittee
looking at the state of the FDA published a report called “FDA Science and
Mission at Risk.”216 The subcommittee found that the FDA is massively
underfunded and understaffed for the responsibilities that it has governing
foods, drugs, medical devices, cosmetics, and dietary supplements.217
William Hubbard, a former FDA associate commissioner commented,

210. Barry Green, Natural Health Product (NHP) Regulation in Canada,
OTTAWASKEPTICS.ORG (May 6, 2008), http://www.ottawaskeptics.org/topics/alternativemedicine/48-alt-med/123-natural-health-product-nhp-regulation-in-canada.
211. For a discussion of the DSNCPA and CGMPs, see supra notes 88-116 and
accompanying text.
212. See Yamaguchi, supra note 137.
213. See Green, supra note 210.
214. See Eberhardie, supra note 127, at 509.
215. For a discussion of dietary supplement regulations in Australia, see supra notes 17789.
216. See Julie Schmit, Report: FDA So Underfunded, Consumers Are Put at Risk, USA
TODAY, Dec. 3, 2007, at 6B, available at http://www.usatoday.com/news/washington/200712-02-fda_N.htm (noting that the subcommittee members were: Allen Roses of Duke
University, an expert in neurology; Gail Cassell, a vice president of Eli Lilly; and Barbara
McNeil, a public health policy expert at Harvard Medical School); see also FDA SUBCOMM.
ON SCI. AND TECH., FDA SCIENCE AND MISSION AT RISK (2007).
217. See FDA SUBCOMM. ON SCI. AND TECH., supra note 216, at 6.
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“[t]hese people were horrified by what they found,” and they determined that
the FDA “cannot even do its job now.”218
Support and criticism of DSHEA, the DSNDCPA, and the CGMPs show
that the debate over the “correct” way to regulate dietary supplements in the
U.S. will likely never cease, as money and lobbying have proved to be
highly influential in the rulemaking process.219 Even though skeptics of the
DSNDCPA and the CGMPs in the U.S. have criticized the rules by pointing
out doomsday scenarios, the truth is that the actual effects on consumer
choice and consumer safety have not yet been realized. No other freemarket economy with a well-developed dietary supplement industry has yet
found a regulatory framework that is either foolproof or free from
controversy. When one adds to the argument that dietary supplement
regulation has only existed in the U.S. since 1994 and that the dietary
supplement market continues to expand each year, it becomes evident that
the proper direction for dietary supplement regulation must be heavily
calculated.
Finally, it does not appear that any of the regulatory frameworks in the
world’s largest dietary supplement markets can be classified as model
systems. Each regulatory framework is both complex and unique to the
market and culture that it serves, and each has its own advantages,
disadvantages, criticisms, and praises.
Commenting on the EU Food Supplements Directive, one author writes,
“[i]t can be seen that the whole area of regulation for food supplements and
traditional herbal remedies is complex and necessary but controversial.”220
Controversy surely is one of the few things that all dietary supplement
regulations have in common. And if the past is any indication, controversy
surrounding the regulation of dietary supplements is here to stay, regardless
of where supplements are sold.
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